17 August 2016
EMA/PDCO/452922/2016
Procedure Management and Committees Support Division

Paediatric Committee (PDCO)

Minutes for the meeting on 20-22 July 2016

Chair: Dirk Mentzer – Vice-Chair: Koenraad Norga

20 July 2016, 08:30- 19:00, room 3A

21 July 2016, 08:30- 19:00, room 3A

22 July 2016, 08:30- 13:00, room 3A

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued).

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

Table of contents

1. Introductions

1.1. Welcome and declarations of interest of members, alternates and experts

In accordance with the Agency's policy on handling of declarations of interests of scientific committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of some meeting participants in upcoming discussions as included in the pre-meeting list of participants and restrictions.

Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 23 or more members were present in the room). All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. Adoption of agenda

The agenda was adopted with amendments.

1.3. Adoption of the minutes

The minutes were adopted with amendments and will be published on the EMA website.

2. Opinions

Disclosure of some information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

2.1. Opinions on Products

2.1.1. Cathine hydrochloride (D-Norpseudoephedrine hydrochloride) - EMEA-001909-PIP01-15

Schuck GmbH; Treatment of obesity / Adjunct therapy for patients with obesity and a body mass index (BMI) of at least 30 for adults and above the 97th percentile for children who failed to achieve adequate therapeutic response with comprehensive weight loss measures alone.

Day 120 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of committee discussion:

Following the day 90 discussion, the applicant completely revised their paediatric clinical development plan in line with the PDCO requests.
The PDCO adopted a positive opinion on the newly proposed paediatric development plan.

2.1.2. Elafibranor - EMEA-001857-PIP01-15

Genfit SA; Treatment of non-alcoholic fatty liver disease (NAFLD), Treatment of non-alcoholic steatohepatitis (NASH) / Treatment of non-alcoholic fatty liver disease (NAFLD)

Day 120 opinion

Gastroenterology-Hepatology

Summary of committee discussion:

The PDCO discussed this application on D120. The responses provided after D90 were acknowledged.

A positive opinion was adopted on D120.

2.1.3. Eculizumab - Orphan - EMEA-000876-PIP07-15

Alexion Europe SAS; Prevention of delayed graft function after solid organ transplantation / Prevention of delayed graft function after kidney transplantation in patients at increased risk of delayed graft function

Day 120 opinion

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

All issues have been addressed and resolved satisfactorily.
The PDCO granted a waiver for eculizumab in children with less than 5 kg body weight. A deferral was granted for the modelling & simulation, clinical and extrapolation studies.
The PDCO adopted a positive opinion.

2.1.4. Angiotensin II - EMEA-001912-PIP01-15

La Jolla Pharmaceutical Company, Inc.; Treatment of Catecholamine-resistant hypotension associated with distributive shock.

Day 120 opinion

Other

Summary of committee discussion:

The PDCO adopted a negative opinion refusing the current proposal.

2.1.5. Autologous cartilage derived cultured chondrocytes - EMEA-001823-PIP01-15

TETEC AG; Treatment of cartilage disorders

Day 120 opinion

Other

Summary of committee discussion:

The applicant's response was considered acceptable and the comments from CAT were acknowledged. A positive opinion was adopted.

2.1.6. derivative of 4H-pyrazolo[3,4-d]pyrimidin-4-one - EMEA-001742-PIP01-14

Boehringer Ingelheim International GmbH; treatment of schizophrenia / Cognitive Impairment Associated with Schizophrenia

Day 120 opinion

Psychiatry

Summary of committee discussion:

The applicant confirmed their acceptance of the adjustments required at Day 90. All outstanding issues being resolved, the PDCO considered the modified proposal acceptable and adopted a positive opinion.

2.1.7. Amlodipine besylate / Perindopril erbumine / indapamide - EMEA-001948-PIP01-16

Zentiva, k.s.; Treatment of essential hypertension

Day 60 opinion

Cardiovascular Diseases

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee the PDCO agrees with the applicant's request for a waiver.
The PDCO recommends granting a waiver for amlodipine besylate / indapamide / perindopril erbumine for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of hypertension.

2.1.8. Ezetimibe / Rosuvastatin (calcium) - EMEA-001941-PIP01-16

Adamed sp z o.o.; Treatment of hypercholesterolaemia

Day 60 opinion

Cardiovascular Diseases

Summary of committee discussion:

The PDCO's view expressed at day 30 was re-discussed and endorsed.
Based on the assessment of this application the PDCO agrees with the applicant's request

for a waiver. The PDCO recommends granting a waiver for Rosuvastatin (calcium) / Ezetimibe for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of hypercholesterolaemia on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

2.1.9. tadalafil / macitentan - EMEA-001961-PIP01-16

Actelion Registration Ltd.; I27.0: Primary pulmonary hypertension / Treatment of Pulmonary Arterial Hypertension

Day 60 opinion

Cardiovascular Diseases

Summary of committee discussion:

The PDCO discussed at D60 the appropriate ground for this waiver.
The PDCO recommends granting a waiver for all subsets of the paediatric population (0 to 18 years of age) in the condition of “Treatment of pulmonary arterial hypertension”.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.10. Humanized IgG1, kappa anti-serum amyloid A and anti-AL amyloid antibody - Orphan - EMEA-001962-PIP01-16

Prothena Therapeutics Limited; Treatment of Light Chain (AL) Amyloidosis

Day 60 opinion

Cardiovascular Diseases / Haematology-Hemostaseology

Summary of committee discussion:

The PDCO confirmed the outcome of the D30 discussion. Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for Humanized IgG1, kappa anti-serum amyloid A and anti-AL amyloid antibody for all subsets of the paediatric population (0 to 18 years of age) in the condition of “Treatment of systemic light-chain amyloidosis”.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.11. (S)-lactic acid - EMEA-001953-PIP01-16

YES Pharmaceutical Development Services GmbH; Pregnancy / Prevention of pregnancy

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of committee discussion:

A positive opinion was adopted on D60.

2.1.12. allopurinol / lesinurad - EMEA-001952-PIP01-16

AstraZeneca AB; hyperuricaemia associated with gout

Day 60 opinion

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee including contributions of external expert(s), the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for lesinurad / allopurinol for all subsets of the paediatric population (0 to 18 years of age) in the condition of “Treatment of hyperuricaemia”.

2.1.13. Allogeneic human neural stem cells genetically modified to express c-MycERTAM, a c-Myc and modified oestrogen receptor fusion protein - EMEA-001969-PIP01-16

ReNeuron Ltd; Sequelae of cerebral infarction

Day 60 opinion

Neurology

Summary of committee discussion:

The PDCO’s view expressed at day 30 was re-discussed and endorsed.
Based on the assessment of this application, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for Allogeneic human neural stem cells genetically modified to express c-MycERTAM, a c-Myc and modified oestrogen receptor fusion protein for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of cerebral infarction.

2.2. Opinions on Compliance Check

The following compliance checks have been put up for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance

2.2.1. Levamisole (hydrochloride) - EMEA-C-001885-PIP01-15-M01

ACE Pharmaceuticals BV; treatment of glomerulonephritis and nephrotic syndrome

Day 30 opinion

Uro-nephrology

Summary of committee discussion:

The PDCO adopted on 22 July 2016 an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision (P/0179/2016) of 08/07/2016.

2.3. Opinions on Modification of an Agreed Paediatric Investigation Plan

2.3.1. Evolocumab - EMEA-001268-PIP01-12-M03

Amgen Europe B.V.; Treatment of mixed dyslipidaemia, Treatment of elevated cholesterol / , Heterozygous Familial Hypercholesterolaemia (HeFH) and Homozygous Familial Hypercholesterolaemia (HoFH) after Prior Lipid-Lowering Therapy in paediatric subjects aged 10 years and above.

Day 60 opinion

Cardiovascular Diseases

Summary of committee discussion:

The PDCO confirmed the outcome of the Day 30 discussion and agreed with the requested changes to the timelines of the paediatric clinical studies.
Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0070/2016 of 18 March 2016).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.2. Linaclotide - EMEA-000927-PIP01-10-M03

Allergan Pharmaceuticals International Limited; Functional Constipation / in children

Day 60 opinion

Gastroenterology-Hepatology

Summary of committee discussion:

The PDCO acknowledged the applicant's responses.
Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that some of the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision.
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.3. Lubiprostone - EMEA-000245-PIP01-08-M03

Sucampo Pharma Europe Ltd.; chronic idiopathic constipation / chronic idiopathic constipation

Day 60 opinion

Gastroenterology-Hepatology

Summary of committee discussion:

The applicant's responses to the D30 questions were acknowledged. In general the response was considered acceptable.
Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision.
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.4. vedolizumab - EMEA-000645-PIP01-09-M04

Takeda Pharma A/S; ulcerative colitis, Crohn's disease

Day 60 opinion

Gastroenterology-Hepatology

Summary of committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0015/2016 of 29 January 2016). The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.5. ixekizumab - EMEA-001050-PIP01-10-M02

Eli Lilly & Company Limited; Treatment of psoriasis vulgaris, Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis and juvenile idiopathic arthritis) / Treatment of moderate to severe chronic plaque psoriasis in paediatric patients from the age of 6 years who are not adequately controlled by topical therapies., Treatment of JIA (including polyarticular arthritis, extended oligoarticular arthritis, sJIA without active systemic features, and ERA including JoAS and JPsA) in paediatric patients from the age of 2 years and for the treatment of sJIA with active systemic features in paediatric patients from the age of 1 year.

Day 60 opinion

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0100/2016 of 15 April 2016). The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.6. piperaquine tetraphosphate / dihydroartemisinin - EMEA-000153-PIP01-07-M04

Sigma-Tau SpA; Uncomplicated malaria caused by Plasmodium falciparum (ICD-10 code B50) / Treatment of uncomplicated malaria caused by Plasmodium falciparum

Day 60 opinion

Infectious Diseases

Summary of committee discussion:

The PDCO has re-discussed the application including the new information submitted since Day 30, along with the assessors' comments.
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.7. Fingolimod hydrochloride - EMEA-000087-PIP01-07-M04

Novartis Europharm Limited; Multiple Sclerosis / Multiple Sclerosis

Day 60 opinion

Neurology

Summary of committee discussion:

The PDCO re-discussed the main issues as outlined at D30. As requested, the applicant provided further clarification between D30 and D60. The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/00117/2013 of 26 April 2013). The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.8. Brexpiprazole - EMEA-001185-PIP01-11-M03

Otsuka Europe Development and Commercialisation Ltd, Zweigniederlassung Frankfurt am Main; Schizophrenia / Treatment of schizophrenia in adolescents 13 to 17 years of age

Day 60 opinion

Psychiatry

Summary of committee discussion:

Based on the review of the rationale submitted by the applicant after Day 30 for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP.
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.9. Lanthanum carbonate hydrate - EMEA-000637-PIP02-10-M05

Shire Pharmaceutical Contracts Ltd; Treatment of hyperphosphataemia

Day 60 opinion

Uro-nephrology

Summary of committee discussion:

The PDCO's requests were discussed with the applicant in a teleconference between Day 30 and Day 60.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0037/2014 of 05 March 2014).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.4. Opinions on Re-examinations

None

2.5. Finalisation and adoption of opinions

3. Discussion of applications

Disclosure of some information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Discussions on Products D90-D60-D30

3.1.1. Recombinant human monoclonal antibody to GM-CSF) - EMEA-001882-PIP01-15

Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis and juvenile idiopathic arthritis) / Treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 1 year of age and older, Treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older

Day 90 discussion

Immunology-Rheumatology-Transplantation

3.1.2. Bivalent anti-human myostatin adnectin recombinant human IgG1-Fc fusion protein - EMEA-001793-PIP01-15

Treatment of Duchenne Muscular Dystrophy / Treatment of Duchenne Muscular Dystrophy in patients aged ≥2 years to <18 years

Day 90 discussion

Neurology

3.1.3. GIVINOSTAT - Orphan - EMEA-000551-PIP02-14

Italfarmaco S.p.A.; Duchenne Muscular Dystrophy / Improvement of symptoms and improvement of disability in DMD affected patients

Day 90 discussion

Neurology

3.1.4. copanlisib - EMEA-001757-PIP02-15

Treatment of all conditions included in the category of malignant neoplasms (except hematopoietic and lymphoid tissue)., Treatment of mature B-cell neoplasms / , Treatment of children with neuroblastoma, Ewing's sarcoma, osteosarcoma or rhabdomyosarcoma who failed one or more prior lines of therapy.

Day 90 discussion

Oncology

3.1.5. Guadecitabine / Guadecitabine - EMEA-001730-PIP02-15

Treatment of acute myeloid leukemia / Adults with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates or unfit for Intensive Remission Induction Chemotherapy, Treatment of pediatric subjects age 3 months or older to less than 18 years with relapsed refractory AML after failure of intensive remission induction chemotherapy

Day 90 discussion

Oncology

3.1.6. Orphan - EMEA-001794-PIP01-15

ReveraGen BioPharma Ltd; Treatment of duchenne muscular dystrophy / Treatment of duchenne muscular dystrophy

Day 90 discussion

Other

3.1.7. Recombinant, CHO cell expressed, fully human IgG1, kappa light chain, monoclonal antibody - Orphan - EMEA-001864-PIP01-15

Dyax Corp.; Hereditary angioedema / Treatment of hereditary angioedema

Day 90 discussion

Other

3.1.8. Ragweed pollen extract (Ambrosia artemisiifolia) - EMEA-001881-PIP01-15

Treatment of allergic rhinitis and/or conjunctivitis / treatment of ragweed pollen allergic rhinitis and/or conjunctivitis

Day 90 discussion

Pneumology - Allergology

3.1.9. Birch bark extract - Orphan - EMEA-001299-PIP02-16

Birken AG; Treatment of epidermolysis bullosa / Treatment of epidermolysis bullosa

Day 60 discussion

Dermatology

3.1.10. Gadolinium - EMEA-001949-PIP01-16

Detection and visualisation of areas with disruption of the blood brain barrier and/or abnormal vascularity for diagnostic purposes

Day 60 discussion

Diagnostic

3.1.11. Recombinant human alpha-glucosidase conjugated with multiple copies of synthetic bismannose-6-phosphate-tetra-mannose glycan - Orphan - EMEA-001945-PIP01-16

Genzyme Europe B.V.; ICD-10: E74.0; Glycogen storage disease (Pompe disease) / Long-term use as an ERT for the treatment of patients with a confirmed diagnosis of Pompe disease (acid α-glucosidase deficiency)

Day 60 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.12. blisibimod - EMEA-001972-PIP01-16

systemic lupus erythematosus

Day 60 discussion

Immunology-Rheumatology-Transplantation

3.1.13. Seletalisib - EMEA-001938-PIP01-16

Primary Immunodeficiency syndrome

Day 60 discussion

Immunology-Rheumatology-Transplantation

3.1.14. MK-8408 / grazoprevir / MK-3682 - EMEA-001981-PIP01-16

Treatment of Chronic Hepatitis C Virus Infection / Treatment of chronic hepatitis C infection of genotypes 1 to 6 with the combination regimen of MK-3682, MK 5172 and MK-8408 in children and adolescents from 3 years to < 18 years of age.

Day 60 discussion

Infectious Diseases

3.1.15. Cannabidiol - Orphan - EMEA-001964-PIP01-16

GW Research Ltd; Treatment of Seizures

Day 60 discussion

Neurology

3.1.16. Human bone marrow-derived allogeneic mesenchymal precursor cells (MPCs) - EMEA-001827-PIP02-16

chronic heart failure

Day 30 discussion

Cardiovascular Diseases

3.1.17. fluoromisonidazolum (18F) - EMEA-001977-PIP02-16

Imaging of hypoxic tissue in Non-small Cell Lung Cancer (NSCLC) for diagnostic purposes, Imaging of hypoxic tissue in Renal Cell Carcinoma (RCC) for diagnostic purposes, Imaging of hypoxic tissue in Gliomas for diagnostic purposes, Imaging of hypoxic tissue in Head and Neck Squamous Cell Carcinoma (HNSCC) for diagnostic purposes

Day 30 discussion

Diagnostic / Oncology

3.1.18. Allogeneic, non-expanded, umbilical Cord blood-derived, hematopoietic mature myeloid and lymphoid cells (NF) / Allogeneic, ex vivo expanded, umbilical Cord blood-derived, hematopoietic CD34+ progenitor cells (CF) - Orphan - EMEA-001913-PIP01-15

Gamida Cell Limited; acute lymphoblastic leukaemia, myelodysplastic syndrome, acute myeloid leukaemia, chronic myeloid leukaemia / haematopoietic reconstitution of patients who are medically indicated for allogeneic haematopoietic stem cell transplantation

Day 30 discussion

Haematology-Hemostaseology

3.1.19. EMEA-001741-PIP02-16

Treatment of Ulcerative Colitis

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.1.20. Autologous CD34+ hematopoietic stem cells transduced ex vivo with EFS lentiviral vector encoding for the human ADA gene - Orphan - EMEA-001974-PIP01-16

Pr Bobby Gaspar; Severe combined immunodeficiency disorder due to adenosine deaminase

deficiency [ADA-SCID] / Treatment of severe combined immunodeficiency disorder due to adenosine deaminase deficiency [ADA-SCID]

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.1.21. tocilizumab - EMEA-000309-PIP03-16

Systemic Sclerosis

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.1.22. T-lymphocytes enriched leukocyte preparation depleted ex vivo of host host-alloreactive T cells using photodynamic treatment - Orphan - EMEA-001980-PIP01-16

Kiadis Pharma Netherlands B.V.; Adjunctive treatment in haematopoietic stem cell transplantation for a malignant disease / Adjunctive treatment to a haploidentical haematopoietic stem cell transplantation with CD34+ selected cells, in patients with a haematological malignancy, for the reduction of morbidity (i.e. incidences and severity of graft versus host disease) and mortality due to infection and relapse.

Day 30 discussion

Immunology-Rheumatology-Transplantation / Oncology

3.1.23. EMEA-001975-PIP01-16

Treatment of influenza

Day 30 discussion

Infectious Diseases

3.1.24. Recombinant Respiratory Syncytial Virus Vaccine with adjuvant - EMEA-001966-PIP01-16

Prevention of RSV disease

Day 30 discussion

Infectious Diseases

3.1.25. EMEA-001970-PIP01-16

ICD10 code A04.7: Enterocolitis due to Clostridium difficile / SER-109 is indicated as a treatment, at the completion of antibiotic therapy, of paediatric patients with active recurrent Clostridium difficile infection to prevent further recurrence

Day 30 discussion

Infectious Diseases

3.1.26. lifitegrast - EMEA-001979-PIP01-16

Treatment of dry eye disease

Day 30 discussion

Ophthalmology

3.1.27. paracetamol / ibuprofen - EMEA-002002-PIP01-16

Treatment of pain

Day 30 discussion

Pain

3.1.28. Fevipiprant - EMEA-001315-PIP02-16

Asthma / Treatment of moderate to severe asthma

Day 30 discussion

Pneumology - Allergology

3.1.29. olodaterol hydrochloride - EMEA-001965-PIP01-16

Treatment of cystic fibrosis

Day 30 discussion

Pneumology - Allergology

3.1.30. Live attenuated, chimeric dengue virus, serotype 4 / Live, attenuated, chimeric dengue virus, serotype 3 / Live, attenuated dengue virus, serotype 2 / Live, attenuated, chimeric dengue virus, serotype 1 - EMEA-001888-PIP01-15

Prevention of dengue fever

Day 30 discussion

Vaccines

3.2. Discussions on Compliance Check

The following compliance checks have been put up for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance

3.2.1. Pitavastatin calcium - EMEA-C-000054-PIP01-07-M04

Kowa Pharmaceutical Europe Co. Ltd.; Treatment of disorders of lipoprotein metabolism and

other lipidaemias

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.2.2. Pitavastatin calcium - EMEA-C-000300-PIP01-08-M04

Kowa Pharmaceutical Europe Co. Ltd.; Treatment of disorders of lipoprotein metabolism and other lipidaemias

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.2.3. icatibant - EMEA-C-000408-PIP01-08-M05

Shire Orphan Therapies GmbH; Treatment of hereditary angioedema (HAE)

Day 30 discussion

Other

3.3. Discussions on Modification of an Agreed Paediatric Investigation Plan

3.3.1. apixaban - EMEA-000183-PIP01-08-M04

Bristol-Myers Squibb / Pfizer EEIG; Prevention of arterial thromboembolism, Prevention of venous thromboembolism / Prevention of venous thromboembolism (VTE) in paediatric subjects (1 to <18 years old) with a newly diagnosed acute lymphoblastic leukemia (ALL) or lymphoma (T or B cell), a functioning central venous access device (CVAD) and receiving PEG L-asparaginase during chemotherapy induction., Prevention of TE in paediatric patients (birth to below 18 years old) with cardiac disease.

Day 30 discussion

Cardiovascular Diseases

3.3.2. selepressin - EMEA-000506-PIP01-08-M02

Ferring Pharmaceuticals A/S; Septic shock / Vasopressor-dependent Septic Shock

Day 30 discussion

Cardiovascular Diseases

3.3.3. Humanised monoclonal antibody IgG2 recognising the interleukin-31 receptor A (IL-31RA) - EMEA-001624-PIP01-14-M01

CHUGAI PHARMA EUROPE LTD; Atopic Dermatitis / Atopic Dermatitis

Day 30 discussion

Dermatology

3.3.4. albiglutide - EMEA-001175-PIP01-11-M04

Glaxo Group Limited; Non-insulin dependent diabetes mellitus / type 2 diabetes mellitus

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.5. Alogliptin benzoate (as alogliptin) - EMEA-000496-PIP01-08-M05

Takeda Development Centre Europe Ltd; Type 2 diabetes melitus

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.6. Sapropterin Dihydrochloride - Orphan - EMEA-001476-PIP01-13-M01

BioMarin International Limited; Hyperphenylalaninemia / BH4 deficiency, Phenylketonuria

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.7. eftrenonacog alfa - Orphan - EMEA-000914-PIP01-10-M03

Biogen Idec Ltd; Hereditary Factor IX Deficiency - D67

Day 30 discussion

Haematology-Hemostaseology

3.3.8. Autologous CD34+ cells transduced with lentiviral vector containing the human Wiskott Aldrich Syndrom Protein gene. - Orphan - EMEA-000786-PIP01-09-M02

Genethon; Treatment of Wiskott-Aldrich syndrome

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.3.9. Delamanid - Orphan - EMEA-001113-PIP01-10-M05

Otsuka Europe Development and Commercialisation Ltd.; Treatment of multi drug resistant tuberculosis / Treatment of multi drug resistant tuberculosis

Day 30 discussion

Infectious Diseases

3.3.10. Elvitegravir - EMEA-000968-PIP02-11-M05

Gilead Sciences International Ltd; Human immunodeficiency virus [HIV]disease resulting in other conditions [ICD-10: B23] / Vitekta is indicated for use with a pharmacoenhancer and other antiretroviral agents for the treatment of HIV-1 infection in paediatric patients aged < 18 years.

Day 30 discussion

Infectious Diseases

3.3.11. Tedizolid phosphate - EMEA-001379-PIP01-12-M02

Merck Sharp & Dohme (Europe), Inc.; Treatment of complicated skin and soft tissue infections / Treatment of complicated skin and soft tissue infections

Day 30 discussion

Infectious Diseases

3.3.12. nusinersen - Orphan - EMEA-001448-PIP01-13-M02

Ionis Pharmaceuticals, Inc.; Spinal muscular atrophy

Day 30 discussion

Neurology

3.3.13. Recombinant Human TriPeptidyl Peptidase 1 (rhTPP1) - Orphan - EMEA-001362-PIP01-12-M03

BioMarin International Limited; Neuronal Ceroid Lipofuscinosis Type 2 (NCL2) / Treatment of Neuronal Ceroid Lipofuscinosis Type 2 (NCL2)

Day 30 discussion

Neurology

3.3.14. zuretinol acetate - Orphan - EMEA-001453-PIP01-13-M01

QLT Ophthalmics (UK), Ltd.; Retinitis Pigmentosa, Leber Congenital Amaurosis / Treatment of patients with Inherited Retinal Disease who have been phenotypically diagnosed as LCA or RP caused by mutations in retinal pigment epithelium protein 65 (RPE65) or lecithin:retinol acyltransferase (LRAT) genes

Day 30 discussion

Ophthalmology

3.3.15. Human recombinant IgG1 monoclonal antibody targeting fibroblast growth factor 23 (FGF23) - Orphan - EMEA-001659-PIP01-15-M01

Ultragenyx Pharmaceutical Inc.; X-linked Hypophosphatemia

Day 30 discussion

Other

3.3.16. Human Thrombin (component 2) / Human Fibrinogen (component 1) - EMEA-001598-PIP01-13-M02

Instituto Grifols, S.A.; Treatment of haemorrhage resulting from a surgical procedure / Supportive treatment in surgery where standard surgical techniques are insufficient for improvement of haemostasis, and as a suture support in vascular surgery

Day 30 discussion

Other

3.3.17. CONCENTRATE OF PROTEOLYTIC ENZYMES ENRICHED IN BROMELAIN - Orphan - EMEA-000142-PIP02-09-M04

MediWound Germany GmbH; Treatment of burns of external body surfaces / Removal of eschar in deep partial and/or full thickness burns

Day 30 discussion

Other / Dermatology

3.3.18. mepolizumab - Orphan - EMEA-000069-PIP02-10-M06

GSK Trading Services Limited; treatment of asthma / add-on treatment for severe refractory eosinophilic asthma

Day 30 discussion

Pneumology - Allergology

3.3.19. Peanut flour - EMEA-001734-PIP01-14-M01

Aimmune Therapeutics; Peanut Allergy / Peanut oral immunotherapy for the reduction in clinical reactivity to accidental exposure in peanut allergic children and adults

Day 30 discussion

Pneumology - Allergology

3.3.20. Reslizumab - EMEA-001202-PIP02-13-M01

Teva Pharmaceuticals Europe; Treatment of asthma / CINQAERO is indicated as add- on treatment in adult patients with severe eosinophilic asthma

Day 30 discussion

Pneumology - Allergology

3.3.21. EMEA-000431-PIP01-08-M09

Glaxo Group Limited; Mixed Asthma / Treatment of asthma where use of a combination product (long acting beta agonist and inhaled corticosteroid) is appropriate

Day 30 discussion

Pneumology - Allergology

4. Nominations

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

4.1. List of letters of intent received for submission of applications with start of procedure 16 August 2016 for Nomination of Rapporteur and Peer reviewer

Summary of committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.2. Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver.

Summary of committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.3. Nominations for other activities

4.3.1. Appointment of PDCO representation at EnprEMA drafting group to work for clinical trial preparedness

Summary of committee discussion:

PDCO members were informed on a planned initiative to establish a temporary ad-hoc Enpr-EMA working group on clinical trial preparedness and invited to express their interest to become a member.

5. Scientific Advice Working Party (SAWP) and Paediatric Committee (PDCO) Interaction

Disclosure of information related to this section cannot be released at the present time as it is deemed

to contain commercially confidential information.

6. Discussion on the applicability of class waivers

Disclosure of some information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Discussions on the applicability of class waiver for products

6.1.1. Seribantumab - EMEA-20-2016

Merrimack Pharmaceuticals U.K. Limited; Treatment of lung carcinoma (small cell and non-small cell carcinoma)/ Seribantumab is indicated in combination with docetaxel or pemetrexed for the treatment of patients with heregulin positive non-small cell lung cancer following prior therapy with a PD-1 or PD-L1 blocking antibody for locally advanced or metastatic disease

Summary of committee discussion:

The applicability of the class waiver as referred to in the Agency's Decision CW/1/2011 to the planned therapeutic indication was confirmed.

Other potential paediatric interest of this medicine suggested by PDCO: none currently identified.

Note: in case of removal from the list of class waivers listed in the Agency's Decision CW/1/2011, the requirements set out in Article 7 and 8 of Regulation (EC) No 1901/2006 of the Agency's Decision CW/0001/2015 shall apply after 36 months from the date of the removal from the list of class waivers.

6.1.2. Avelumab - EMEA-21-2016

Merck KGaA; Treatment of ureter and bladder carcinoma, treatment of kidney and renal pelvis carcinoma (excluding nephroblastoma, nephroblastomatosis, clear cell sarcoma, mesoblastic nephroma, renal medullary carcinoma and rhabdoid tumour of the kidney)/ Treatment of urothelial cancer

Summary of committee discussion:

The applicability of the class waiver as referred to in the Agency's Decision CW/1/2011 to the planned therapeutic indication was confirmed.

Other potential paediatric interest of this medicine suggested by PDCO: treatment of paediatric solid tumours.

Note: in case of removal from the list of class waivers listed in the Agency's Decision CW/1/2011, the requirements set out in Article 7 and 8 of Regulation (EC) No 1901/2006 of the Agency's Decision CW/0001/2015 shall apply after 36 months from the date of the removal from the list of class waivers.

6.1.3. Danirixin - EMEA-22-2016

GlaxoSmithKline Trading Services Limited; All classes of medicinal products for treatment of chronic obstructive pulmonary disease (COPD) (excluding chronic lung diseases associated with long-term airflow limitation, such as asthma, bronchopulmonary dysplasia, primary cilia dyskinesia, obstructive lung disease related to graft-versus-host disease after [bone-marrow] transplantation)/ Maintenance treatment to relieve symptoms of COPD in adult patients

Summary of committee discussion:

The applicability of the class waiver as referred to in the Agency's Decision CW/0001/2015 to the planned therapeutic indication was confirmed.

Other potential paediatric interest of this medicine suggested by PDCO: treatment of influenza, treatment of respiratory syncytial virus infection.

6.1.4. EMEA-23-2016

Eli Lilly and Company Limited; Treatment of Alzheimer's disease / slowing of disease progression in patients with early Alzheimer's disease (defined as the continuum of Mild Cognitive Impairment due to Alzheimer's disease and mild dementia of the Alzheimer's type)

Summary of committee discussion:

The applicability of the class waiver as referred to in the Agency's Decision CW/1/2011 to the planned therapeutic indication was confirmed.

Other potential paediatric interest of this medicine suggested by PDCO: none currently identified.

7. Discussion on the inclusion of an indication within a condition in an agreed PIP/waiver

7.1. Discussion on the possibility to include an indication within a condition in an agreed PIP/waiver

7.1.1. Semaglutide - EMEA-001441-PIP01-13

Novo Nordisk A/S; Reduction of the risk of major cardiovascular adverse events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and high cardiovascular risk/ Treatment of type 2 diabetes mellitus

Summary of committee discussion:

The PDCO concluded that the proposed indication 'Reduction of the risk of major cardiovascular adverse events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and high cardiovascular risk', falls under the scope of the Agency's Decision P/0095/2015, as the indication is considered to be

covered by the condition 'treatment of type 2 diabetes mellitus'.

7.1.2. Brentuximab vedotin - EMEA-000980-PIP01-10-M04

Takeda Pharma A/S; Anaplastic large cell lymphoma to cover adult T-cell leukaemia/lymphoma, hepatosplenic T-cell lymphoma, angiocentric lymphoma, angio-immunoblastic T-cell lymphoma, T-cell lymphoma/leukaemia, intestinal T-cell lymphoma

Summary of committee discussion:

The proposed new indications are not covered by existing EMA Decisions.

7.1.3. Liraglutide - EMEA-000128-PIP01-07-M07

Novo Nordisk A/S; Treatment of type 2 diabetes/Prevention of major adverse cardiovascular events (MACE) in adults with type 2 diabetes mellitus and high cardiovascular risk as an adjunct to standard of care therapy.

Summary of committee discussion:

The PDCO was of the view that the proposed indication "prevention of major adverse cardiovascular events (MACE) in adults with type 2 diabetes mellitus and high cardiovascular risk as an adjunct to standard of care therapy falls under the scope of the above mentioned Decision, as the indication is considered to be covered by the condition "treatment of type 2 diabetes mellitus" listed in the Agency Decision.

8. Annual reports on deferrals

Note: The annual reports on deferrals to be noted by the members of the PDCO are flagged in the Annex B.

9. Organisational, regulatory and methodological matters

9.1. Mandate and organisation of the PDCO

9.1.1. Proposals for optimisation of PDCO plenary meetings

PDCO Chair: Dirk Mentzer

Summary of committee discussion:

The Committee discussed the continuous process improvement proposals to continue to streamline plenary discussions.

9.2. Coordination with EMA Scientific Committees or CMDh-v

9.2.1. Committee for Medicinal Products for Human Use (CHMP)

Summary of committee discussion:

The PDCO members were informed about 2 products, Cervarix and Ryzodeg, for which the CHMP adopted positive opinions recommending paediatric indications during their meeting in June 2016.

9.2.2. Recommendations on eligibility to PRIME – report from CHMP

Summary of committee discussion:

The members of the PDCO took note of the products for which the CHMP adopted the recommendation for PRIME eligibility during their meeting in June 2016. The individual outcomes are listed in PRIME Monthly Report on EMA website.

9.2.3. Strategic Review and Leaning Meeting to be held in Brussels on 19-21 October 2016 –registration opened

PDCO Chair: Koenraad Norga

Summary of committee discussion:

The Committee noted a draft agenda for the meeting.

9.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

9.3.1. Non-clinical Working Group: D30 Products identified

PDCO member: Jacqueline Carleer

Summary of committee discussion:

The chair of the NcWG identified the products which will require NcWG evaluation and discussion.

9.3.2. Formulation Working Group

PDCO member: Brian Aylward

Summary of committee discussion:

Relevant products for FWG discussion were identified.

9.3.3. Juvenile animal studies with anti-cancer medicines

PDCO member: Jacqueline Carleer

Summary of committee discussion:

The Committee discussed the process for commenting and finalising the draft report on the analyses of juvenile animal studies with anti-cancer report.

9.3.4. Guideline on influenza vaccines

Summary of committee discussion:

The committee was informed of the positive outcome of the written procedure for the PDCO adoption of guideline. The CHMP will adopt the final version of the guideline at its July plenary meeting.

9.4. Cooperation within the EU regulatory network

9.4.1. European Network of Paediatric Research (Enpr) - European Medicines Agency (EMA) representation at PDCO plenary meetings

Summary of committee discussion:

Following up on proposals made during the Enpr-EMA annual workshop be PDCO representatives on how to improve interaction and communication between networks and PDCO, it is proposed to regularly invite network representatives for generic discussions on specific therapeutic areas at PDCO meetings (plenary, ORGAM). PDCO members are invited to identify therapeutic areas or general topics for such discussions.

9.5. Cooperation with International Regulators

None

9.6. Contacts of the PDCO with external parties and interaction with the Interested Parties to the Committee

9.6.1. Recommendations for Pharmacological Clinical Trials in Children with Irritable Bowel Syndrome (IBS) from the Rome Foundation Paediatric Subcommittee on Clinical Trials

PDCO Member: Johannes Taminiau

Summary of committee discussion:

The Committee was informed of the recommendation of the scientific group in the area of IBS.

9.7. PDCO work plan

9.7.1. PDCO work plan 216 mid-year report and draft PDCO work plan 2017

PDCO Chair: Dirk Mentzer

Summary of committee discussion:

The Committee noted a report on the objectives and activities planned in 2016 and was updated on the status of the draft work plan 2017.

9.8. Planning and reporting

None

10. Any other business

10.1.1. Templates for the summaries of the PDCO opinions

Summary of committee discussion:
EMA presented new templates for the public summaries of the evaluation of paediatric investigation plans and waivers. The templates have been revised and aligned with those of other EMA documents aimed at the general public. A set of criteria for updating the summaries was also proposed. Additionally, the process for drafting and reviewing the summaries has been updated. It is expected that summaries in the new template will start to be published in Q4 2016.

10.1.2. Survey to Committee members, alternates and concerned NCA staff on the service / support provided by Committee Secretariats

Summary of committee discussion:

The Committee was reminded to participate in the survey on the service / support provided by EMA Committee Secretariats' Service.

10.1.3. Training for PDCO alternate

PDCO member: Jorrit Gerritsen

Summary of committee discussion:

A training for new alternate member on applicable system and tools took place in the margins of the meeting.

11. Breakout sessions

11.1.1. Paediatric oncology

Summary of committee discussion:

The participants discussed from a general perspective the clinical experience with using anti-cancer medicines in different lines of treatment, and where this is more based on extrapolation considerations or specific data. Participants were invited to comment on the draft report of the analysis of the juvenile studies with anti-cancer medicines, and how to disseminate the results to paediatric oncology clinical researchers.

11.1.2. Neonatology

Summary of committee discussion:

The group discussed organisational issues regarding the upcoming review of the neonatal guideline, the INC meeting in September as well as issues for studies in the area of necrotising enterocolitis (NEC).

11.1.3. Paediatric inventories

Summary of committee discussion:

The participants discussed the comments received following the recent public consultation of the latest inventory of paediatric therapeutic needs dealing with respiratory conditions.

12. List of participants

List of participants including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 20-22 July 2016 meeting.

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Dirk Mentzer	Chair	Germany	No interests declared	
Karl-Heinz Huemer	Member	Austria	No interests declared	
Koenraad Norga	Member (Vice-Chair)	Belgium	When chairing the meeting: To be replaced for discussions, final deliberations and voting on:	EMEA-001882-PIP01-15; EMEA-001175-PIP01-11-M04; EMEA-000431-PIP01-08-M09;EMEA-22-2016; EMEA-000069-PIP02-10-M06
Jacqueline Carleer	Alternate	Belgium	No interests declared	
Dimitar Roussinov	Member	Bulgaria	No restrictions applicable to this meeting	
Adriana Andrić	Member	Croatia	No interests declared	
Jaroslav Sterba	Member	Czech Republic	No interests declared	
Marianne Orholm	Member	Denmark	No interests declared	
Marta Granström	Alternate	Denmark	No interests declared	
Irja Lutsar	Member	Estonia	No interests declared	
Ann Marie Kaukonen	Member	Finland	No interests declared	
Maija Pihlajamaki	Alternate	Finland	No interests declared	
Sylvie Benchetrit	Member	France	No interests declared	
Immanuel Barth	Member	Germany	No interests declared	
Sabine Scherer	Alternate	Germany	No interests declared	
Ágnes Gyurasics	Member (CHMP member)	Hungary	No interests declared	
Brian Aylward	Member	Ireland	No interests declared	
Sara Galluzzo	Member	Italy	No interests declared	
Dina Apele-Freimane	Member	Latvia	No interests declared	
Carola de Beaufort	Member (CHMP alternate)	Luxembourg	No restrictions applicable to this meeting	
John-Joseph Borg	Member	Malta	No interests declared	
Maaike van Dartel	Member	Netherlands	No interests declared	
Siri Wang	Member	Norway	No interests declared	
Marek Migdal	Member	Poland	No interests declared	
Jolanta Witkowska-Ożogowska	Alternate	Poland	No interests declared	
Helena Fonseca	Member	Portugal	No interests declared	
Hugo Tavares	Alternate	Portugal	No interests declared	
Dana Gabriela Marin	Member (CHMP alternate)	Romania	No interests declared	
Stefan Grosek	Member	Slovenia	No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Fernando de Andrés Trelles	Member	Spain	No interests declared	
Maria Jesús Fernández Cortizo	Alternate	Spain	No interests declared	
Ninna Gullberg	Member	Sweden	No interests declared	
Angeliki Siapkara	Member	United Kingdom	No interests declared	
Martina Riegl	Alternate	United Kingdom	No interests declared	
Riccardo Riccardi	Member	Healthcare Professionals' Representative	No participation in discussions, final deliberations and voting on:	EMEA-001945-PIP01-16
Jorrit Gerritsen	Alternate	Healthcare Professionals' Representative	No interests declared	
Johannes Taminiau	Member	Healthcare Professionals' Representative	No interests declared	
Doina Plesca	Alternate	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Günther Auerswald	Member	Patients' Organisation Representative	No participation in discussions, final deliberations and voting on:	EMEA-000914-PIP01-10-M03
Paola Baiardi	Alternate	Patients' Organisation Representative	No interests declared	
Avula Shivaram	Expert - via telephone*	EMA	No restrictions applicable to this meeting	
Claire Beuneu	Expert - via telephone*	Belgium	No interests declared	
Suzanne Kaul	Expert - in person*	Germany	No interests declared	
Marion Haberkamp	Expert - via telephone*	Germany	No interests declared	
Shiva Ramroop	Expert - in person*	United Kingdom	No restrictions applicable to this meeting	
Meeting run with support from relevant EMA staff				

* Experts were only evaluated against the agenda topics or activities they participated in.

13. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Paediatric investigation plan (PIP) (section 2.1 Opinion on PIPs and section 3.1 Discussions on PIPs)
A paediatric investigation plan (PIP) is a development plan aimed at ensuring that the necessary data are obtained through studies in children, when it is safe to do so, to support the authorisation of a medicine for children. Pharmaceutical companies submit proposals for PIPs to the European Medicines Agency's Paediatric Committee (PDCO). This Committee is responsible for agreeing or refusing the plan.

Compliance checks (section 2.2 Opinions on Compliance check, section 3.2 Discussions on Compliance check)
A compliance check may be necessary before any application for marketing authorisation (even for an adult indication) can be considered valid, if there was no deferral for at least one of the studies agreed in the PIP, or after the due date of initiation or completion of a study/measure. The same applies to some regulatory applications for authorised products, as described above.

Modification of an Agreed Paediatric Investigation Plan (section 2.3 Opinions on Modification of an agreed PIP, section 3.3 Discussions on Modification of an agreed PIP)
The development plan for a medicine can be modified at a later stage as knowledge increases. Modifications can also be made if the applicant encounters such difficulties with the implementation of a PIP, which render it unworkable or no longer appropriate.
In some cases, studies can be deferred until after the studies in adults have been conducted. This ensures that research in children is done only when it is safe and ethical to do so. Even when studies are deferred, the PIP will include details of the paediatric studies and their timelines.

Class waiver (section 6 Discussion on the applicability of class waiver)
As some diseases do not affect children (for example Parkinson's disease), the development of medicines for these diseases should not be performed in children. In these cases, a PIP is not required and it will be waived**.** For more information on the classes of diseases subject to waivers, see class waivers.

Annual reports on deferrals (section 8)
If the medicinal product is approved in the EU, annual reports on the deferred measures in the PIP must be submitted to the Agency.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/